Skip to content Skip to sidebar Skip to footer

All Posts

HomeAll Posts
June 29, 2026

When Elon Musk Notices Your Dividend: Coca-Cola’s KO Windfall and the Cash-Flow Cast -( $BRK.B $FMC $KO $MCD $NVDA $TSLA )

Wall Street is having a moment of sugary clarity: in a market obsessed with AI, EVs and space tourism, it’s an old-school soda dividend that just reminded everyone where the real cash flow power still resides.

When Elon Musk Met Warren Buffett’s Coke Habit

Tesla’s Elon Musk (NASDAQ: TSLA) is not easily impressed, but Berkshire Hathaway’s (NYSE: BRK.B) Coca-Cola (NYSE: KO) dividend stream has managed to do what rocket launches and humanoid robots cannot: it left him publicly floored. The Yahoo Finance/Moneywise piece details how Berkshire’s decades-long stake in Coca-Cola now spins off a dividend windfall so large that it borders on financial performance art.. Buffett’s strategy was simple but excruciatingly patient: buy KO, sit still, let the brand compound, and watch the dividend checks grow into something that looks more like a corporate annuity than a quarterly payout. Musk’s reaction, laced with his trademark online wit, effectively turned Coca-Cola’s dividend into a meme—and, inadvertently, into a masterclass in what happens when time and yield collaborate.

The Dividend Barbell: Coke, Chips and Cash Flows

While Berkshire’s KO income stream is the star of the current narrative, the broader market is quietly assembling a dividend “barbell” that pairs classic consumer staples with modern AI hardware royalty. On one end sits NVIDIA (NASDAQ: NVDA), the semiconductor titan whose AI accelerators power everything from data centers to the latest market bubble debates. NVDA pays a token annual dividend of $0.04 per share—about 0.02% yield—disbursed as $0.01 quarterly, with the latest payment on April 1, 2026 following a March 11 ex-dividend date. This payout is less a cash-income story and more a signaling device: NVDA’s dividend consumes only about 0.8% of earnings, backed by roughly $96.6 billion in fiscal 2026 free cash flow and supplemented by a colossal $41.1 billion returned via buybacks. In other words, NVDA is the friend who shows up to the dividend party, pays a symbolic cover charge, and then spends the rest of the evening repurchasing itself into scarcity.

FMC: The Workhorse Yield Behind the Scenes

Slide to the other side of the barbell and you find FMC Corporation (NYSE: FMC), a leading global agricultural sciences company and a far less meme-able but far more cash-forward name in the basic materials and ag-chem arena. FMC currently pays an annual dividend of $0.32 per share, translating to a yield of about 2.75%, with quarterly installments of $0.08—the next scheduled for July 16, 2026 to holders of record as of the June 30 ex-dividend date. The company’s payout ratio looks quirky on earnings because of recent profit pressure, but sits at about 7.34% of cash flow, suggesting the dividend is anchored in real operating cash rather than accounting optics. That puts FMC in the “quietly competent” bucket: not the stuff of viral posts, but the kind of recurring cash stream that can stabilize an income-oriented portfolio while investors argue online about whether AI valuations are rational or merely recreational.

McDonald’s: Where Yield Meets Global Scale

If Coca-Cola is Buffett’s dividend comfort food, McDonald’s (NYSE: MCD) is the market’s global yield drive-thru. MCD currently serves up an annual dividend of $7.44 per share, yielding roughly 2.75%, with its most recent quarterly payment of $1.86 per share hitting investor accounts on June 16, 2026 after a June 2 ex-dividend date. The golden arches have boosted their dividend for 49 consecutive years, compounding payouts at about 7.30% annually over the past five years, while maintaining a payout ratio near 61% of earnings and 48% of cash flow—high enough to be meaningful, low enough to stay comfortably sustainable. For investors, MCD offers a case study in what happens when durable brand equity, disciplined capital allocation and global scale all conspire in favor of the shareholder.

The Investor Takeaway: From “High on Coke” to High-Conviction Income

The “High on Coke” moment isn’t just a clever headline—it’s a reminder that dividends can quietly redraw the wealth map over time. Berkshire’s KO position illustrates how a long-duration commitment to a cash-generative brand can produce a dividend profile that even ultra-wealthy innovators find eye‑opening. Also, in a market where Elon Musk can be startled by a soda dividend and NVIDIA can fund a global AI build‑out with pocket‑change payouts, the message to investors is disarmingly simple: you don’t have to choose between innovation and income—you just have to size them intelligently.

The Sources

  1. Yahoo Finance / Moneywise – “‘High on Coke’: Elon Musk floored by Berkshire Hathaway’s Coca-Cola dividend windfall. How to tap in and get rich”
    https://finance.yahoo.com/markets/stocks/articles/high-coke-elon-musk-floored-101500459.html
  2. NVIDIA (NVDA) Dividend Date & History – Tickeron
    https://tickeron.com/dividends/NVDA/
  3. FMC Corporation (FMC) Dividend Yield, Date & History – MarketBeat
    https://www.marketbeat.com/stocks/NYSE/FMC/dividend/
  4. McDonald’s Corporation (MCD) Dividend Yield, Date & History – MarketBeat
    https://www.marketbeat.com/stocks/NYSE/MCD/dividend/

June 29, 2026

Gold to $4,900? Why Goldman Says the Party Isn’t Over -( $GLD $GS )

Goldman’s (GS) latest gold call still paints a bullish long‑term picture, but it comes wrapped in a more cautious, almost deadpan Wall Street shrug about the road between here and that glittering 4,900-5400 an ounce horizon. In other words: the party is still on, but the bouncer is now checking macro credentials at the door.

A New Gold Script on Wall Street

Gold has spent 2026 reminding investors that “safe haven” does not mean “straight line.” After spectacular gains driven by central bank buying, geopolitical risk, and lingering inflation anxiety, the metal has traded sideways to modestly lower, hovering around the low‑4,000s per ounce and giving back its year‑to‑date edge. Into this uneasy calm, Goldman Sachs has reiterated a structurally bullish long‑term stance on gold, but now with a lower near‑term ceiling and a frank acknowledgment that the Federal Reserve, not the bullion desk, is running the show. That slight tonal shift—still optimistic, now more self‑aware—is exactly what is catching institutional eyes.

Goldman’s Glimmer: High Target, Lower Halo

Goldman’s core message is deceptively simple: even after trimming expectations, the bank still sees gold materially higher by the end of 2026. The headline target has migrated, not vanished.

  • Goldman now pegs year‑end 2026 gold around 4,900 per ounce after cutting its prior forecast by 500 dollars as Fed cuts this year have moved from “baseline” to “wishful thinking.”
  • In parallel work, the bank has highlighted a broader 2026 destination near 5,400, flagging this as a reasonable long‑term waypoint if central bank demand remains robust and financial conditions eventually ease.
  • Even with the haircut, Goldman’s updated range still implies upside from current spot levels, just with more macro turbulence priced in and less fantasy about a painless glide path.

The firm’s research desk reportedly has also conceded that its model for central‑bank gold purchases had underestimated buying by more than 70%, a quietly astonishing miss that nonetheless reinforces the idea of a structural bid under the market. When the quants discover their “exogenous demand shock” is actually just the real world, investors tend to lean in.

A Market of Many Targets (and Even More Caveats)

Goldman is not pitching this trade in a vacuum; other major houses are busily marking their own targets to a more data‑dependent reality. The collective effect is a market that remains bullish on gold in theory but is learning to live with drawdowns in practice.

  • Deutsche Bank recently took a scalpel—and then a cleaver—to its gold view, cutting its Q3 2026 forecast by roughly 22% to about 4,300 per ounce on the back of stickier inflation and renewed rate‑hike chatter.
  • BMO Capital Markets has trimmed its second‑half average gold price estimate to around 4,625, still constructive but measurably cooler than earlier projections.
  • Other global players, including Bank of America, UBS, and Morgan Stanley, have shifted to a more cautious tone, warning that near‑term downside risks have risen and that previously aggressive price targets may be harder to hit without a friendlier Fed..

At the same time, a cluster of strategists continues to float numbers well north of Goldman’s latest guide, with some 2026 forecasts drifting toward the 6,000 per ounce neighborhood. The dispersion itself has become a tell: the gold market is not debating whether the regime has changed—just how far, how fast, and with how many macro bruises along the way.

Why Gold’s Story Still Sells

Strip away the day‑to‑day volatility and gold’s current narrative has the kind of layered complexity institutional allocators quietly admire. It is not just an inflation hedge or a geopolitical fear barometer anymore; it is a multi‑factor expression of a crowded, complicated cycle.

  • Central banks remain steady buyers, with Goldman estimating average monthly purchases around 60 tonnes through 2026, despite temporary pauses when prices spike.
  • Investor surveys suggest roughly 70% of respondents still expect gold to settle above 5000 per ounce within a year, underscoring that the bullish narrative, while bruised, is very much alive.
  • Citi and others have recently nudged down short‑term targets as seasonal softness and shipping‑route tensions weigh on sentiment, yet they retain longer‑term projections of 5,000 or more once the current macro fog lifts.

In short, this is the rare asset whose bull case has become more nuanced without collapsing, a sort of macro Rorschach test that still resolves into “own at least something” for many CIOs.

How Investors Can Read (and Trade) the Script

For investors, the emerging message from Goldman and its peers is refreshingly sober: gold is not broken, it is just behaving like a serious asset in a serious cycle. That makes it less of a heroic “all‑in” trade and more of a deliberate portfolio character actor.

  • Strategic allocators can possibly treat gold as a long‑term core position sized to tolerate 10% –20% drawdowns on the path toward those mid‑4,000s to mid-5000s targets.
  • Tactically minded investors may favor scaling in on macro‑driven pullbacks—when rate‑hike odds spike or risk assets wobble—rather than chasing strength after each geopolitical headline.
  • Risk managers, meanwhile, can frame gold less as a mystical inflation hedge and more as a liquid, diversifying exposure that tends to become interesting exactly when other carefully curated plans stop working.

The net result is an asset whose story remains compelling, even if the dialogue has grown sharper and the jokes a little drier. Gold, in the current Wall Street script, is not done—it is just demanding that investors earn the upside, one macro plot twist at a time.

GLD: The Ticker Behind Gold’s Big Talk

For investors who prefer their gold in ticker form rather than safety‑deposit‑box form, SPDR Gold Shares (GLD) remains the default way to express a view on the metal. The fund tracks the price of physical gold held in trust, and with a recent price of 369.36 dollars per share and a market value north of 130 billion dollars, it is effectively the institutional “meeting room” for the entire bullion trade.

Over the past twelve months, GLD has treated holders to a robust double‑digit ride, posting roughly a 24% gain as gold rallied from the low‑300s into a 52‑week range that stretches from 300.96 to as high as 509.70. The path, however, has been anything but linear: after notching that 509.70 peak in late January, GLD has since pulled back more than 25% from the high, leaving the ETF down about 5% year‑to‑date and trading below both its 50‑day and 200‑day moving averages. Technically, the fund looks like a classic “bullish trend in need of a breather.” A one‑year total return north of 20% sits alongside a short‑term profile marked by weaker momentum, with recent data showing GLD in a drawdown phase even as its trailing one‑year performance remains well ahead of many broader commodity peers. In practice, that means strategic investors are still sitting on healthy profits, while tactical traders are now eyeing support zones rather than chasing breakouts and quietly hoping the next leg higher arrives before their patience—and their sophisticated humor—runs out.

The Sources

  1. Goldman Sachs Reduced Its Gold Price Target for the End of 2026 – Yahoo Finance
  2. Goldman Sachs Lops $500 Off Gold Target on No Fed Cuts This Year – Bloomberg
  3. Goldman Sees Downside Risks to Its 2026 Gold Price Target – Investing.com
  4. Deutsche Bank Cuts Gold Outlook: New $4,300 Target Amid Rate Hike Expectations – IndexBox
  5. The Federal Reserve’s Interest Rate Hikes Are the Top Threat! Following Goldman Sachs and Deutsche Bank, Another Investment Bank Has Lowered Its Gold Price Target – Moomoo
  6. Gold Price Forecast 2026: What the Major Banks Are Predicting Now – GoldSilver.com
  7. The Price of Gold Is Flat in 2026. Some Experts Are Still Bullish—But Not in the Short Term. Here’s Why – Investopedia
    • (Tool output was truncated; use this page via direct navigation on Investopedia and search the article title.)
  8. Gold Price Forecast | US Payrolls Lift Rate Bets – Capital.com
  9. Gold Price Prediction June 2026: What Experts Are Forecasting – MoneyMagpie
  10. Goldman Sachs Has Crucial Message for Gold Investors in 2026 – TheStreet
  11. SPDR Gold Shares (GLD) – Perplexity Finance Snapshot
  12. SPDR Gold Shares GLD Performance – Morningstar
  13. SPDR Gold Shares (GLD) Performance History – Yahoo Finance
  14. GLD ETF – Returns, Sharpe Ratio & Risk Metrics – MarketXLS
  15. GLD: SPDR Gold Shares – State Street Global Advisors (Fund Page)

June 29, 2026

AI Chuck E. Cheeses, Vera Supercomputers and Investor Gravity -( $AMWL $HPE $NVDA $SMWB )

Mark Cuban’s latest thought experiment starts where most AI debates end: with a pile of empty data centers and a lot of bruised egos. Instead of forecasting doom, he wonders whether an AI bust could become the most unexpected jobs program since the mall food court. If hulking server barns morph into Chuck E. Cheese outlets and SMB hubs, Cuban argues, entrepreneurs and small businesses—which account for roughly 60% of new jobs annually—could soak up the slack.

It’s a surprisingly bullish take on a bearish scenario: even if AI demand wobbles, the physical and human capital does not evaporate; it gets repurposed. Investors used to thinking in straight lines may need to sharpen their taste for economic recycling and second acts.

Agentic AI And The Vera CPU Engine

While Cuban imagines data centers serving pizza, Los Alamos National Laboratory is quietly turning them into scientific brain trusts. Its upcoming Mission, Vision and Veritas supercomputers—codesigned with Hewlett Packard Enterprise (HPE) and powered by NVIDIA’s Vera Rubin platform—aim to unlock “agentic AI” for science, where AI agents autonomously form hypotheses, choose tools, run simulations and iterate. For NVIDIA Corporation (NVDA), Vera’s custom Olympus cores, LPDDR5 memory and high-speed fabric have already delivered roughly 7x performance on URSA agent workloads versus the Crossroads x86 supercomputer and over 3x gains on Branson Monte Carlo simulations.

LANL’s roadmap positions Mission and Vision, expected around 2027, as successors to existing Grace/Grace Hopper–based systems like Venado, extending a decade-long NVIDIA–LANL collaboration on CPU and GPU architectures. For investors, that signals that AI infrastructure isn’t just about serving chatbots; it underpins nuclear security, materials science, biomedical research and energy modeling—domains that don’t tend to disappear in the next upgrade cycle.

Behavioral Science Meets Healthcare Alpha

A recent Nature Human Behaviour–linked study surfaced in healthcare sector coverage highlights how human psychology interacts with health outcomes and policy, adding another layer to the AI narrative. While the article sits within the healthcare vertical, the implications stretch into biotech and medtech, where AI-driven experimentation increasingly relies on understanding not just molecules, but the humans who take them.

For publicly traded healthcare names i.e Amwell (AMWL), that blend of behavioral insight and data-driven experimentation reinforces a simple investor theme: AI is not a standalone story; it is a force multiplier for existing scientific and commercial moats. Companies that can connect clinical data, behavioral patterns and algorithmic modeling will likely enjoy more durable advantages than those simply “adding an LLM” to the pitch deck.

Similarweb’s Multi Seven-Figure Signal

On the commercial side of the spectrum, Similarweb Ltd. (SMWB) has secured a multi–seven figure, multi-year engagement centered on digital intelligence and data. The deal underscores how enterprise buyers are not just purchasing AI tools; they are locking in traffic analytics, competitive intelligence and web performance data that feed AI models and decision engines.

For SMWB, recurring high-ticket contracts suggest that “picks and shovels” for the digital economy—clean traffic datasets, benchmarking tools, and observability—remain valuable even as AI narratives gyrate. If Cuban’s hypothetical AI bust turns server farms into arcades, the underlying demand for knowing who is clicking, watching and buying online should remain intact.

The Investor-Magnetic Takeaway

Put Cuban’s Chuck E. Cheese scenario, LANL’s Vera-powered agentic AI, behavioral healthcare research and Similarweb’s data deals together, and a pattern emerges. The AI cycle is not a binary bet on “boom forever” versus “total collapse”; it looks more like a series of capital reallocations around computation, data and human behavior.

For investors, several themes stand out:

  • AI infrastructure has deep, non-hype use cases in national security and scientific research (NVDA, HPE and partners).
  • Enterprise data and analytics providers like SMWB can remain relevant across cycles, supplying the streams that AI and humans both drink from.
  • Healthcare and behavioral research will increasingly intersect with AI, shaping how new therapies and policies are designed and tested.
  • Even in a downside scenario, physical assets and talent tied to AI can be repurposed into new SMB-driven ecosystems, sustaining job creation and local growth.

In other words, whether the future looks more like Mission and Vision or more like a strip of neon-lit arcades, the long-term game is about owning the computation, the data, and the behavioral insight. Would you rather underwrite the pizza, the supercomputer, or the traffic map that tells both where the customers are?

The Sources

  1. Mark Cuban on AI “collapsing” and data centers becoming Chuck E. Cheeses – Barchart
  2. NVIDIA Vera CPU and agentic scientific AI at Los Alamos National Laboratory – NVIDIA Blog
  3. Nature Human Behaviour–linked healthcare/behavior study (via Yahoo Finance Healthcare sector coverage) – Yahoo Finance Healthcare
  4. Similarweb multi–seven-figure, multi-year digital intelligence deal – Yahoo Finance Markets
June 27, 2026

June 26, 2026 – AI Trade Cools as Wall Street Rotates to Value This Week -( $AMWL $EPRX $ILLR $MODD $MU $SMWB Rise! )

U.S. equities closed the week with a more defensive tone as the S&P 500 and Nasdaq broke their two‑week winning streaks under pressure from stretched AI and semiconductor leaders, while the Dow managed a modest gain on the back of value and defensive buying.

Investors used recent strength in names like Nvidia Corporation (NVDA), Advanced Micro Devices Inc. (AMD), Apple Inc. (AAPL), and Microsoft Corporation (MSFT) to take profits, rotating toward cash‑generative industrials, financials, and health care as they waited for fresh macro clarity.

Vista View: We see this as a normalization phase in the AI trade rather than the end of the secular theme, with leadership broadening and dispersion increasing across sectors and tickers.

Index Scorecard: Growth Stumbles, Value Holds

  • The S&P 500 Index (GSPC) finished lower on the week, giving back part of its recent gains as growth and momentum factors lost steam.
  • The Nasdaq Composite (IXIC) underperformed, with high‑beta tech and semiconductor stocks bearing the brunt of AI‑valuation fatigue.
  • The Dow Jones Industrial Average (DJI) edged higher, supported by more reasonably priced industrials, financials, and health care names that benefitted from the rotation away from crowded mega‑cap growth.

Investor Takeaway: Broad U.S. equity exposure remains supported, but leadership is changing beneath the surface—index‑level calm masks growing intra‑market volatility and factor rotation.

AI & Semis: Micron and Qualcomm Shine Amid Volatility

The AI complex remained the center of the equity story, but this week brought more nuance and stock‑specific differentiation.

  • Micron Technology Inc. (MU) delivered a strong earnings print and upbeat guidance, fueling a sharp post‑earnings rally as investors rewarded its positioning in AI‑driven memory and data‑center demand.
  • Qualcomm Inc. (QCOM) highlighted incremental AI opportunities in data‑center and edge computing, projecting meaningful new revenue streams and reigniting interest in its broader AI roadmap beyond smartphones.
  • In contrast, bellwethers like Nvidia Corporation (NVDA) and Advanced Micro Devices Inc. (AMD) saw ongoing profit‑taking as investors questioned the sustainability of AI capital‑expenditure intensity and increasingly lofty expectations embedded in current valuations.

Vista View: We continue to favor AI‑exposed names where valuation, capital‑intensity, and balance‑sheet quality remain aligned with realistic adoption curves—stock selection is becoming more critical than simply owning the broad “AI basket.”

Mega‑Cap Tech: Pricing Power Meets Skepticism

Mega‑cap tech remained under scrutiny as markets weighed exceptional profitability against incremental signs of demand sensitivity and regulatory risk.

  • Apple Inc. (AAPL) and Microsoft Corporation (MSFT) drew attention for further price adjustments in key software and cloud offerings, reviving debates about the limits of pricing power at scale.
  • The Nasdaq 100 (NDX) reflected this tension, as gains in select AI‑hardware and chipmakers struggled to offset weakness in some platform and software names.

Investor Takeaway: Even best‑in‑class platforms can experience multiple compression when the market questions how much more pricing and AI enthusiasm can be pulled forward—multiple expansion is no longer a given.

Macro Corner: PCE Confirms “Higher for Longer”

The macro backdrop this week revolved around the latest Personal Consumption Expenditures (PCE) inflation reading, the Federal Reserve’s preferred gauge.

  • The May PCE data came in hotter than the prior month but broadly in line with expectations, keeping the “bumpy disinflation” narrative intact rather than sparking a new inflation scare.
  • Markets continue to price a “higher for longer” Fed stance, with little conviction behind near‑term rate‑cut hopes but also limited fear of a renewed tightening cycle.
  • Rate‑sensitive assets and long‑duration growth names felt the impact as investors reassessed discount‑rate assumptions and re‑priced future cash flows more conservatively.

Vista View: The Fed remains data‑dependent, but the bar for a rapid pivot lower in rates is high. Portfolio construction should assume a longer period of restrictive policy relative to the last decade’s norm.

Sector & Style Rotation: Cash Flows Back in Focus

Rotations this week underscored a subtle but important shift in market psychology.

  • Value, quality, and income factors outperformed as investors favored companies with visible cash flows, disciplined capital allocation, and more modest expectations.
  • Energy, financials, and select industrials benefited from this rotation, while parts of communication services and consumer discretionary traded unevenly in response to company‑specific headlines.
  • Defensive sectors such as utilities and health care provided ballast as investors looked for ballast against AI and tech volatility.

Investor Takeaway: This is an environment that rewards balance—allocations that combine selective AI exposure with durable cash‑flow franchises may offer better risk‑adjusted outcomes than an all‑in growth stance.

Cross‑Asset Check: FX, Metals, and Crypto

Cross‑asset price action provided additional context for equity investors.

  • The U.S. dollar gained ground versus the euro (EURUSD), reflecting shifting growth and rate differentials and reinforcing tighter financial conditions for non‑U.S. borrowers.
  • Gold and silver advanced, with gold pushing higher and silver following suit, signaling renewed demand for precious metals as both inflation hedges and alternative stores of value.
  • Bitcoin (BTC‑USD) and Ether (ETH‑USD) remained in consolidation, with crypto markets treating recent rebounds as opportunities to resize risk rather than re‑enter full‑risk mode.

Vista View: Persistent dollar strength and firm precious metals highlight that macro uncertainty is far from resolved; crypto remains more of a speculative satellite allocation than a core holding for most investors.

What This Means for Investors

For now, the market narrative has shifted from “AI melt‑up” to “AI digestion.” Strong micro stories from Micron Technology Inc. (MU) and Qualcomm Inc. (QCOM) coexist with valuation and policy uncertainty for leaders like Nvidia Corporation (NVDA), Advanced Micro Devices Inc. (AMD), Apple Inc. (AAPL), Microsoft Corporation (MSFT), and other mega‑cap franchises.

The key questions heading into the second half of 2026:

  • How sustainable is AI capital‑expenditure intensity from hyperscalers and enterprises?
  • How quickly will PCE and other inflation gauges converge toward the Fed’s target?
  • Will leadership broaden beyond a tight cluster of AI winners, or will narrow breadth re‑assert itself?

At Vista Partners, we continue to emphasize:

  • Selective exposure to AI and semiconductor leaders with disciplined capital allocation and clearer visibility on incremental returns.
  • Balanced sector positioning that includes financials, industrials, and defensives to temper factor and valuation risk.
  • A macro‑aware framework that respects higher‑for‑longer rates and cross‑asset signals from FX, rates, and commodities.

VP Watchlist Updates

Amwell® (NYSE: AMWL) a leading provider of a comprehensive SaaS-based software platform for technology-enabled healthcare, closed at $9.19, +9.02% over the last 5-days.

Eupraxia Pharmaceuticals Inc. (EPRX, $6.60, +1.85% over the last 5-days), a clinical-stage biotechnology company leveraging its proprietary Diffusphere™ technology designed to optimize local, controlled drug delivery for applications with significant unmet need, announced (May 5) the first Eosinophilic Esophagitis Endoscopic Reference Score (EREFS) data from its ongoing Phase 1b/2a part of the RESOLVE trial evaluating EP-104GI for the treatment of eosinophilic esophagitis (“EoE”). These data were also presented at the ongoing Digestive Disease Week (“DDW”) conference in Chicago. “The EREFS is an important, validated visual index of severity of EoE disease in the esophagus of patients. It measures edema, rings and strictures and other visible markers of disease often associated with symptoms. Today’s data demonstrated improvement in two key outcomes with EP-104GI in the treatment of EoE: first, that a full injection protocol of 20 injections resulted in more pronounced improvement than a protocol with fewer injections and less coverage area within the esophagus; second, with the higher number of injections, a consistent response in both the inflammatory and fibrotic sub scores of EREFS was observed,” said Dr. James A. Helliwell, Chief Executive Officer of Eupraxia. “This EREFS data being reported at DDW is consistent with the improvements we have seen in EoE symptoms and tissue health (EoEHSS) and suggests improvement in inflammation, fibrosis and the associated narrowing of the esophagus.”

Modular Medical, Inc. (NASDAQ: MODD, $4.94, +19.90% on Friday), a leader in innovative, patient-centric insulin delivery, announced ( June 26) that the Pivot™ tubeless insulin patch pump is now shipping to physician offices for training. Upon completion of training, these pumps will be presented to potential patients in the next few days and weeks. The Company intends to expand the roster of practices that offer Pivot over the coming months. This is another significant milestone in the deployment of Pivot. Modular Medical looks forward to updating the market when these first patients are using the pump to deliver insulin. The Pivot pump is purpose-built for adults with diabetes on daily injections who have faced cost, complexity, and usability barriers with traditional pump systems. This group represents an estimated 70% of insulin-dependent adults who remain on multiple daily injections, a multi-billion-dollar opportunity within the diabetes technology market.

MODD announced (June 24) that the Pivot™ tubeless insulin patch pump is now commercially available. This marks the start of real-world patient use, and the Company’s transition to a commercial-stage medical device company. As only the second fully electronic, tubeless insulin pump available in the United States, Pivot is designed to make pump therapy simpler to learn and easier to live with. Its removable two-part design and 3 mL reservoir, intuitive interface, and flexible, wearable form factor support everyday activities, such as showering and sports, with no battery recharging required – all while maintaining clinical accuracy and connectivity. “Reaching commercial availability is a transformational milestone that marks Modular Medical’s transition from a development-stage company to a revenue-generating commercial business,” said Jeb Besser, Chief Executive Officer of Modular Medical. “As only the second fully electronic tubeless pump on the U.S. market, Pivot is positioned to serve a large, underserved ‘almost-pumper’ population. With first shipments beginning this week, we are focused on disciplined execution, as we scale adoption and seek to build long-term value for patients and shareholders.”

On (June 4) the launch of PivotPump.com, a patient-focused website designed to support individuals seeking a simpler path to insulin pump therapy. This launch follows the Company’s receipt of U.S. Food and Drug Administration (“FDA”) clearance in April 2026 for its Pivot™ insulin delivery system. The FDA clearance represents a significant milestone in Modular Medical’s strategy to expand access to insulin pump technology, particularly among individuals historically underserved by existing solutions. The Company remains on track for commercial launch in the fall of 2026. Pivot is designed for people living with diabetes who rely on daily insulin injections, as well as those who have encountered technological, usability, or cost-related barriers with traditional pump systems. The system emphasizes simplicity and ease of use for the patient and full access to clinical information for the clinician to reduce adoption friction. The PivotPump.com website provides accessible, educational content on insulin pump therapy and highlights the Company’s focus on real-world usability and supporting patients in evaluating and adopting pump-based diabetes care.

Similarweb Ltd. (NYSE: SMWB, $5.60, +12.22% over the last 5-days), a leading digital data and analytics company powering critical business decisions, announced (June 15) that it has surpassed $300 million in Annual Recurring Revenue (ARR) and signed two multi-year enterprise contracts, each representing seven-figure ARR commitments. Collectively, these contracts represent approximately $47 million in Total Contract Value to be recognized over the next three years and were signed during the second quarter of 2026.

Triller Group Inc (Nasdaq: ILLR, $4.46,+184.08% over the last 5-days), a technology and media company operating Triller App, a social media and live-streaming platform focused on music, sports, fashion and culture, together with AGBA Group, a Hong Kong-based financial-services and platform business with longstanding operations in wealth distribution, healthcare and related services across Asia, today announced that it has entered into definitive agreements to acquire a significant position providing economic exposure to SpaceX to be held as a strategic treasury asset on the Company’s balance sheet.

The Sources

  1. Yahoo Finance – “Stock market today: S&P 500, Nasdaq snap 2-week win streak as AI jitters pressure tech”
    https://finance.yahoo.com/markets/live/stock-market-today-sp-500-nasdaq-snap-2-week-win-streak-as-ai-jitters-pressure-tech-231347821.html[finance.yahoo]
  2. CNBC – “Stock market today: Live updates” (June 25, 2026)
    https://www.cnbc.com/2026/06/25/stock-market-today-live-updates.html[writing.wisc]
  3. Yahoo Finance – “Stock market today: Dow, S&P 500, Nasdaq futures rise as Micron, Qualcomm ease AI jitters”
    https://ca.finance.yahoo.com/news/stock-market-today-dow-sp-500-nasdaq-futures-rise-as-micron-qualcomm-ease-ai-jitters-232650645.html[ca.finance.yahoo]
  4. Yahoo Finance – “Stock market today: Dow rises, S&P 500 and Nasdaq slip as Micron soars, Apple drags Big Tech lower”
    https://uk.finance.yahoo.com/news/stock-market-today-dow-sp-500-nasdaq-futures-rise-as-micron-qualcomm-ease-ai-jitters-232650645.html[uk.finance.yahoo]
  5. Yahoo Finance – “Stock market today: S&P 500, Nasdaq eye rebound from tech rout with Micron in focus”
    https://ca.finance.yahoo.com/news/stock-market-today-dow-sp-500-nasdaq-futures-slip-as-ai-trade-doubts-grow-230105138.html[ca.finance.yahoo]
  6. XTB – Daily summary: “Will the S&P 500 close the week with a loss? Find out what drove the market today”
    https://www.xtb.com/int/market-analysis/news-and-research/daily-summary-will-the-s-p-500-close-the-week-with-a-loss-find-out-what-drove-the-market-today[xtb]
  7. KuCoin – “Crypto Daily Market Report – June 26, 2026”
    https://www.kucoin.com/news/articles/crypto-daily-market-report-june-26-2026[kucoin]

June 26, 2026

Patching Into a Takeover? How Pivot Puts Modular Medical Possibly on Abbott and Insulet’s Radar -( $ABT $BBNX $DXCM $MDT $MMED $MODD $PODD $TNDM )

Modular Medical, Inc. (NASDAQ: MODD) is stepping out of the development shadows and onto Wall Street’s main stage with the commercial debut of its Pivot tubeless insulin patch pump and a new patient-facing digital front door at PivotPump.com—signaling a full transition into commercial-stage diabetes tech and, potentially, into the M&A conversation of the larger device players circling the “almost-pumper” market.

A New Player Steps Onto the Diabetes Tech Stage

San Diego–based Modular Medical is positioning Pivot as a simpler, more affordable entry point into insulin pump therapy for adults still injecting multiple times per day—a cohort the company describes as “almost pumpers” in a multi‑billion‑dollar opportunity. Pivot, a tubeless insulin patch pump, recently achieved FDA 510(k) clearance, paving the way for U.S. commercialization and allowing Modular to shift from a development story to a commercial execution story.

In late June, Modular announced that Pivot is now commercially available in the U.S., with shares of MODD reacting positively as investors began to underwrite a revenue ramp rather than just a regulatory timeline. The company plans a phased rollout starting with high‑volume endocrinology practices and expanding to broader metropolitan markets, aiming to reach those who have long viewed traditional pumps as too complex, too intimidating, or simply too expensive.

The Pivot Patch Pump: A Simpler Take on Pumping

Pivot is designed as a removable, tubeless insulin patch pump intended to reduce the friction points that keep injection‑dependent adults from switching to pump therapy. The system uses a disposable cartridge and infusion set that Modular has already begun producing in validation lots, a key manufacturing milestone that helps de‑risk commercial‑scale production and supports a broader roll‑out.

Unlike traditional durable pumps that can look and feel like a lifetime commitment, Pivot aims to present as a lower‑complexity, more “plug‑and‑play” option, with a focus on intuitive use and streamlined training. For many patients whose interaction with diabetes tech has been limited to a glucometer and a calendar reminder, Pivot is pitched as the on‑ramp rather than the finish line.

From R&D Story to Commercial-Stage Narrative

The critical inflection for Modular has been the transition from R&D milestones—510(k) submissions, IRB approvals, and validation lots—to commercial headlines that talk in present tense rather than future conditional. After years as a development‑stage insulin delivery company, the FDA clearance of its first patch pump and the subsequent U.S. availability of Pivot effectively re-rate the narrative from “will they launch?” to “how fast can they scale? To fund that pivot, the company has leaned on the capital markets with a series of offerings, but currently only has5.541M Shares Outstanding and a public float of 2.22M according to Yahoo finance after its most recent raise on April 19 and a reverse split on March 26. Management has consistently guided that proceeds would support commercialization, supply chain optimization, and manufacturing scale‑up for the MODD1 and Pivot platforms, effectively turning what was once dilution for development into funding for deployment and commericalization.

The Digital Front Door: PivotPump.com

If every modern medical device needs both hardware and a narrative, PivotPump.com is Modular’s attempt to control the latter. The newly launched site is explicitly pitched as a patient‑focused hub aimed at individuals searching for a “simpler path” to insulin pump therapy, with educational content that bridges the psychological gap between daily injections and committing to a device. Rather than a sterile corporate brochure, Modular’s online presence leans toward accessible language and visual storytelling that matches its target demographic: adults who may be digitally savvy but clinically cautious. For clinicians and diabetes care and education specialists, the site also functions as a reference point to understand where Pivot fits in a crowded landscape of pumps, pens, and patch solutions.

Training, Gamification, and the “Almost Pumper” Experience

Modular has not stopped at hardware; it has also leaned into education by collaborating with Level Ex, a developer known for gamified medical training, to build interactive training modules around the Pivot pump. The company has previewed a “Level One”‑style experience designed to make both onboarding and ongoing use feel more like a guided app journey than an instruction‑manual slog. This focus on training is strategic: diabetes care specialists play an outsized role in recommending pumps, and anything that shortens the learning curve reduces friction for both prescribers and patients. For investors, this adds an intangible but important moat—experience design—that can matter as much as incremental hardware features in adoption curves..

Competitive Landscape: The Diabetes Tech Neighborhood

Modular is entering a glucose neighborhood already populated by heavyweight neighbors. Abbott Laboratories (NYSE: ABT) has built a franchise around its FreeStyle Libre continuous glucose monitoring (CGM) system, increasingly integrated into digital ecosystems and automated insulin delivery partnerships. Dexcom, Inc. (NASDAQ: DXCM) continues to expand its CGM footprint globally, with its G‑series devices becoming standard of care for many insulin‑dependent patients and a cornerstone in hybrid closed‑loop systems. On the pump side, Medtronic plc (NYSE: MDT) and its MiniMed franchise remain entrenched in durable pump therapy, while Tandem Diabetes Care, Inc. (NASDAQ: TNDM) offers tubed pumps that lean into algorithmic control and interoperability. Insulet Corporation (NASDAQ: PODD) has carved out a leadership position in tubeless patch pumps with its Omnipod platform, effectively defining the category Pivot is now entering.

Why Pivot Is Different Enough to Matter

While Modular is not claiming to reinvent the insulin pump from a pure feature standpoint, it is explicitly targeting the underserved “almost pumper” segment—adults who are clinically appropriate for pump therapy but remain on injections due to cost, complexity, or perceived hassle. Its value proposition centers on simplicity, affordability, and a more approachable on‑ramp rather than the fully robotic, closed‑loop experience that dominates high‑end pump marketing. The manufacturing progress on disposable cartridges and infusion sets, plus the move into commercial availability, indicates that the company has at least partially de‑risked the “can they build it at scale?” question. The strategic launch of PivotPump.com and gamified training reinforces a customer‑experience‑first strategy that plays well with both patients and educators, potentially enabling faster uptake in those high‑volume endocrinology practices that Modular is initially targeting.

Who Might Want to Buy Modular Medical?

With Pivot now commercially available and the company demonstrating capital access plus manufacturing progress, the logical next question from institutional investors is whether Modular is building a standalone franchise or a bolt‑on acquisition candidate. In diabetes tech, history suggests that differentiated assets with clear patient segments often become strategic M&A targets for larger players looking to fill portfolio gaps or accelerate innovation cycles.

Below are some of the more plausible strategic acquirers that could find Modular’s Pivot platform additive to their diabetes portfolios:

  • Abbott Laboratories (NYSE: ABT)
    • Abbott’s FreeStyle Libre CGM franchise could benefit from owning a simple, tubeless patch pump that targets adults new to pump therapy, creating a broader integrated “Libre + Pivot” style offering.
    • For Abbott, a lower‑complexity pump could complement, rather than cannibalize, any future higher‑end automated insulin delivery solutions.
  • Dexcom, Inc. (NASDAQ: DXCM)
    • Dexcom is a CGM pure‑play without an in‑house insulin pump platform, instead partnering with pump makers for automated insulin delivery systems.
    • Owning a straightforward, “almost‑pumper” focused patch pump like Pivot could tighten Dexcom’s ecosystem around first‑time pump users and expand monetization per patient.
  • Medtronic plc (NYSE: MDT) / MiniMed (MMED)
    • Medtronic’s MiniMed portfolio that was rolled out into its own public company earlier this year skews heavily toward traditional durable pumps and advanced closed‑loop systems.
    • Pivot could give Medtronic or MiniMed a more accessible, lower‑complexity option aimed at adults who may not be ready for premium, feature‑rich pumps—essentially a feeder system into its broader portfolio.
  • Insulet Corporation (NASDAQ: PODD)
    • As the category leader in tubeless patch pumps with Omnipod, Insulet might view Pivot as either incremental share or a way to segment offerings by price and complexity.
  • Tandem Diabetes Care, Inc. (NASDAQ: TNDM)
    • Tandem’s strength is in advanced, algorithm‑driven pumps rather than simple patch systems.
    • Pivot could be a way for Tandem to enter the tubeless patch space with an offering optimized for first‑time pumpers, creating a natural progression path into its more advanced platforms.
  • CeQur (private) but relatively cash rich with a recent $100M raise and Beta Bionics (NASDAQ: BBNX)
    • CeQur and Beta Bionics are focused on novel insulin delivery approaches, including wearable devices and automated systems, and could see Pivot as a complementary product that broadens their reach into simpler use cases.
    • For both, acquiring a commercial‑stage, FDA‑cleared patch pump with a clear “almost‑pumper” positioning could accelerate market access and diversify revenue streams.

In aggregate, Modular’s profile—commercial‑stage, targeted patient segment, FDA‑cleared patch pump, active capital markets access—reads like a textbook description of an eventual bolt‑on target for an established diabetes franchise craving incremental innovation without rebuilding the platform from scratch..

What Investors Will Likely Watch Next

As Pivot moves from headline to bedside, investors will likely focus on:

  • Early adoption trends in initial launch geographies and high‑volume endocrinology practices.
  • Evidence that the “almost‑pumper” positioning resonates with both clinicians and patients in real‑world use.
  • Gross margin trajectory as manufacturing scales and supply chain optimization initiatives funded by recent capital raises take hold.
  • The pace and scope of any integrations or partnerships with CGM providers or digital health platforms, which could act as a prelude to strategic interest from larger players.

For now, Modular Medical has cleared the critical hurdle of moving from concept to commercial reality. In a diabetes tech market where giants tend to dominate the closed‑loop end of the spectrum, Pivot’s bet is refreshingly straightforward: keep it simple, keep it affordable, and meet patients exactly where they are—still injecting, but finally ready to pivot.

Learn More

Paul DiPerna, founder of Modular Medical, Inc and legacy inventor of insulin pumps and other medical devices, shares why he created the Pivot™ Insulin Delivery System and potential advantages of Pivot™ compared to daily insulin injections.

The Sources

  1. Modular Medical Announces Commercial Availability of Pivot Tubeless Insulin Patch Pump
    https://finance.yahoo.com/healthcare/articles/modular-medical-announces-commercial-availability-121700614.html
  2. Modular Medical Transitions To Commercial Stage With Pivot Insulin Patch Pump
    https://finance.yahoo.com/healthcare/articles/exclusive-modular-medical-transitions-commercial-120105470.html
  3. Modular Medical Launches New Website for Pivot Tubeless Insulin Patch Pump (PivotPump.com)
    https://ca.finance.yahoo.com/news/modular-medical-launches-website-pivot-120000588.html
  4. Modular Medical Achieves Key Manufacturing Milestone for Pivot Tubeless Insulin Patch Pump
    https://finance.yahoo.com/news/modular-medical-achieves-key-manufacturing-133000481.html
  5. Modular Medical Receives FDA 510(k) Clearance for Pivot Tubeless Insulin Patch Pump
    (example coverage)
    https://www.morningstar.com/news/accesswire/1156363msn/modular-medical-receives-fda-510k-clearance-for-pivot-tubeless-insulin-patch-pump
  6. Modular Medical Receives IRB Approval to Deliver Insulin Using Pivot Patch Pump
    https://finance.yahoo.com/news/modular-medical-receives-irb-approval-133000205.html
  7. Modular Medical Announces FDA Clearance of the MODD1 Insulin Pump
    https://finance.yahoo.com/news/modular-medical-announces-fda-clearance-203500932.html
  8. Modular Medical Announces Pricing of Upsized $9.4 Million Public Offering
    https://finance.yahoo.com/news/modular-medical-announces-pricing-upsized-123500667.html
  9. Modular Medical Announces $12M Private Placement
    https://www.drugdeliverybusiness.com/modular-medical-announces-12m-private-placement/
  10. Modular Medical Announces Proposed Public Offering (late 2025)
    https://finance.yahoo.com/news/modular-medical-announces-proposed-public-221500321.html
  11. Modular Medical Announces $12.0 Million Public Offering Priced at a Premium to Market
    https://finance.yahoo.com/news/modular-medical-announces-12-0-142700002.html[finance.yahoo]
  12. Modular Medical Announces Pricing of $3.4 Million Registered Direct Offering
    https://finance.yahoo.com/markets/stocks/articles/modular-medical-announces-pricing-3-235000347.html
  13. Modular Medical Starts Production of Validation Lots for Pivot Pump Set
    https://finance.yahoo.com/news/modular-medical-starts-production-validation-135605935.html
  14. Modular Medical, Inc. (MODD) – Quote, News & Press Release Feed
    https://finance.yahoo.com/quote/MODD/
    Press release list: https://finance.yahoo.com/quote/MODD/press-releases/
  15. Modular Medical – News Aggregation (StockTitan)
    https://www.stocktitan.net/news/MODD/

June 26, 2026

Inside the New Metabolic Gold Rush: How Sanofi’s Tzield, Modular Medical’s Pivot Pump and GLP‑1 Weight‑Loss Drugs Are Reshaping Diabetes Care -( $AZN $GPCR $LLY $MODD $NVO $PFE $SNY )

Wall Street has a new favorite subplot in the diabetes and obesity saga: a three-act story where Sanofi (SNY) shores up the autoimmune front, Modular Medical (MODD) quietly rewires insulin delivery, and the GLP‑1 heavyweights audition next‑gen obesity drugs on the ADA stage. Together, they sketch a future where diabetes care looks less like a chronic crisis and more like a fully financed turnaround.

Act I: Sanofi’s Tzield Buys Time – And Optionality

Sanofi’s Tzield (teplizumab‑mzwv) has stepped into a rarefied role: a disease‑modifying antibody for type 1 diabetes that’s designed to delay the march to full‑blown, insulin‑dependent disease. The FDA has granted accelerated approval to Tzield in children 8–17 with stage 3 type 1 diabetes to slow the decline of their own insulin production, extending its earlier positioning as the first drug to delay onset of stage 3 in stage 2 patients. Regulators have also accepted a supplemental biologics application for priority review to push the age window lower, aiming to include children as young as one year with stage 2 disease and a target action date in late April 2026. If successful, that expansion would effectively move Sanofi’s addressable market upstream, where each “extra year” before insulin dependence isn’t just a clinical win but a compounding economic and quality‑of‑life asset for families and payers.

Why Tzield Matters To Investors

For long‑term investors, Tzield’s story is not just about revenue per vial; it’s about where in the disease curve Sanofi chooses to compete. By targeting stage 2 and early stage 3 type 1 diabetes, the company inserts itself into the high‑value window where preserving endogenous insulin can alter lifetime costs and complications. That positioning not only supports pricing power but also strengthens Sanofi’s broader diabetes franchise narrative in a world increasingly obsessed with GLP‑1‑driven obesity headlines. The accelerated and priority review paths give investors a concrete regulatory catalyst stack—each label expansion reinforcing Tzield’s platform potential and Sanofi’s execution credibility. In a market that routinely rewards “pathway optionality,” Tzield looks like a strategic foothold in immune‑mediated metabolic disease rather than a one‑off product.

Act II: Modular Medical’s Pivot Pump Unplugs Legacy Insulin Delivery

While Sanofi works upstream on immune modulation, Modular Medical (NASDAQ: MODD) is going after a more prosaic but highly levered pain point: the daily grind of insulin delivery. The company has recently secured FDA 510(k) clearance for Pivot, its next‑generation tubeless insulin patch pump, and is now rolling out a new website built around the question, “Is it time to pivot away from multiple daily injections?” The Pivot system is designed to simplify pump therapy for physicians and patients who have historically found legacy pumps too complex, too fiddly, or simply too intimidating to prescribe and use. By leaning into connectivity and simplicity rather than feature overload, Modular Medical is effectively targeting the very real adoption gap between sophisticated technology and everyday clinic workflow, which is estimated to be approximately a $3 billion dollar market that they call the adult “almost-pumpers,” people managing diabetes who haven’t adopted traditional pumps due to complexity, cost, or training barriers.

A Small Cap Taking Aim At A Big Installed Base

Investors have long known that insulin pump penetration remains stubbornly below its theoretical potential, constrained by training, inertia, and the perceived hassle factor. Pivot’s tubeless design, combined with a web‑first educational push, is clearly calibrated to lower those switching costs and pull multiple‑daily‑injection patients into the device ecosystem. For a small‑cap name, the math is straightforward: modest share gains from a very large, structurally underpenetrated pool of insulin‑requiring patients can move the revenue needle quickly. If Modular Medical can convince even a small fraction of primary care‑driven practices to “pivot” alongside their patients, the operating leverage could be more exciting than the hardware itself.

Act III: GLP‑1 Heavyweights Rewrite The Obesity Playbook

On the other side of the metabolic ledger, obesity therapies are undergoing a transformation that feels more like a platform arms race than an incremental product cycle. At the American Diabetes Association Scientific Sessions in New Orleans, Eli Lilly (LLY) and Novo Nordisk (NVO) showcased new GLP‑1 pills and injectable candidates while competitors and fast followers used the same stage to signal their own ambitions.. Lilly, already leading the injectable obesity market, presented Phase 3 data on its triple‑agonist retatrutide, which targets GLP‑1, GIP, and glucagon receptors and produced approximately 28% weight loss—about 70 pounds over 80 weeks—in the TRIUMPH‑1 obesity study. Novo and Lilly also highlighted that prescriptions for Novo’s oral Wegovy pill surpassed 3 million within five months of launch, underscoring the demand for more convenient, non‑injectable options.

Beyond Weekly Shots: Pills, Triples, And Monthly Dosing

The competitive script is evolving beyond “who has the best weekly shot.” Lilly’s Foundayo, a newly launched small‑molecule GLP‑1 pill, is already viewed as a future blockbuster, while other players like Structure Therapeutics (GPCR) and AstraZeneca (AZN) are pushing mid‑stage oral GLP‑1 candidates that could reach the market around 2029 if Phase 3 data cooperate. Pfizer (PFE), unwilling to sit out the sequel after its earlier GLP‑1 setbacks, rolled out Phase 2b data on berobenatide, a new injectable it acquired via its roughly 10 billion dollar purchase of Metsera, showing around 16% weight loss at higher weekly doses and about 12% placebo‑adjusted weight loss at 28 weeks in a separate maintenance study. The company is positioning berobenatide as a “foundational medicine” with 10 planned or ongoing Phase 3 trials and an eye toward both weekly and potentially monthly dosing regimens later in the decade.

The Payment Plot Twist: Medicare Joins The Cast

No modern obesity story is complete without the payor subplot, and this one is finally getting interesting. Lilly and Novo are actively working to improve insurance coverage for GLP‑1 weight‑loss medications, arguing that the long‑term cardiometabolic benefits justify broader access. In the near term, millions of Medicare beneficiaries are poised to gain access to these drugs with out‑of‑pocket costs reportedly around 50 dollars per month, a potential inflection point for volume that investors have been waiting for. If that access persists and expands, GLP‑1s could migrate from “elite benefit” to a more standard component of cardiometabolic care, with all the volume, pricing, and policy debates that implies.

One Metabolic Theme, Multiple Investable Angles

Taken together, Tzield, Modular Medical’s (MODD) Pivot, and the new class of obesity drugs share a common thread: shifting diabetes and obesity management from late‑stage firefighting to earlier, more elegant intervention. Sanofi is trying to buy patients time before insulin dependence, Modular Medical is simplifying life once insulin is unavoidable, and GLP‑1 leaders are attacking the obesity and type 2 diabetes axis with escalating pharmacologic sophistication. For investors, this translates into a portfolio of uncorrelated but thematically linked exposures—immune modulation, device adoption, and obesity pharmacology—that all ride the same long‑duration megatrend: the global, policy‑supported push to bend the cardiometabolic cost curve. The market will, of course, oscillate between rewarding near‑term prescription curves and long‑dated pipeline readouts, but the underlying demand drivers are more structural than cyclical at this point.

A Brief Note Of Sophisticated Caution

Amid the excitement, the usual caveats apply: immunotherapies like Tzield must continue to demonstrate durable benefit and acceptable safety in younger children; devices like Pivot have to navigate reimbursement, training, and real‑world adherence; and the GLP‑1 race will be shaped not only by efficacy but by tolerability, convenience, and political scrutiny over drug costs. The sector, in other words, offers plenty of catalysts—but also ample room for sentiment swings and valuation indigestion. For investors willing to live with those swings, the current setup feels less like a speculative trade and more like an evolving franchise opportunity across multiple modalities of metabolic care. In Wall Street terms, this isn’t just a story about who sells the most injections this quarter—it’s about who gets written into the standard of care over the next decade.

Learn More Here

The Sources

  1. Sanofi – Tzield US approval and label expansion updates (press releases and background)
    https://www.sanofi.com/en/media-room/press-releases/2026/2026-06-12-22-09-58-3311349
    https://www.sanofi.com/en/media-room/press-releases/2026/2026-01-05-06-00-00-3212420
    https://www.sanofi.com/en/media-room/press-releases/2026/2026-04-22-Sanofis-Tzield-approved-in-the-US-to-delay-the-onset-of-stage-3-type-1-diabetes-in-young-children
  2. Clinical and prescribing background on Tzield (efficacy, safety, indication)
    https://www.tzield.com/about-tzield/efficacy-and-safety
    https://www.sanofi.com/assets/countries/canada/docs/products/prescription-products/Tzield_RMP/MAT-CA-2400962_TZI_RMP-Tool-HCP-Guide-EN-Approved.pdf
  3. Sanofi SEC filing referencing Tzield priority review
    https://www.stocktitan.net/sec-filings/SNY/6-k-sanofi-current-report-foreign-issuer-e0eb0782364b.html
  4. Modular Medical – Corporate site and Pivot / MODD1 positioning
    https://www.modularmedical.com
  5. Modular Medical – FDA 510(k) clearance for the Pivot tubeless insulin patch pump
    https://www.drugdeliverybusiness.com/modular-medical-fda-clearance-pivot-pump/
    https://www.massdevice.com/modular-medical-fda-clearance-pivot-pump/
  6. CNBC – “GLP-1s: Lilly, Novo, Pfizer look to new weight loss drugs” (ADA 2026 coverage, Foundayo, berobenatide, Medicare coverage)
    https://www.cnbc.com/2026/06/13/glp-1s-lilly-novo-pfizer-look-to-new-weight-loss-drugs.html
  7. BioPharma Dive – ADA ’26 metabolic/GLP‑1 conference recap (retatrutide, Pfizer berobenatide data)
    https://www.biopharmadive.com/news/ada-2026-lilly-retatrutide-pfizer-berobenatide-roche-enicepatide/822208/
  8. ScienceDaily – New oral GLP‑1 pill for type 2 diabetes and weight loss (additional context on GLP‑1 oral therapies)
    https://www.sciencedaily.com/releases/2026/06/260614011850.htm

June 25, 2026

Hot PCE Print, Cold AI Hype: Big Tech Stumbles as Dow and Small Caps Quietly Lead on June 25, 2026 -( $DIA $DPC $EPRX $ILLR $MU Rise! )

US equities closed Thursday in a deceptively mixed fashion, with headline indices masking a meaningful leadership shift under the surface. The S&P 500 slipped modestly, -.01% to 7357.49, the Nasdaq fell more sharply by .46% to 25,358.60, and the Dow (51,920.62, +.14%) and Russell 2000 (3007.86, +.71%) managed to grind higher as investors digested a hotter‑than‑expected PCE inflation report and continued to reprice the once untouchable AI and Big Tech trade. Against that macro backdrop, today’s tape reads less like a classic “risk-off” day and more like a market methodically rotating away from crowded growth winners into cyclicals, defensives, and small caps that had been left behind.

Hot PCE keeps the Fed in play

At the center of today’s narrative was the latest read on the Fed’s preferred inflation gauge, the personal consumption expenditures (PCE) price index. Core PCE — which strips out food and energy — came in hotter than policymakers and investors would have preferred, reinforcing the idea that disinflation progress has stalled just shy of the Fed’s 2% target. Headline PCE also printed on the warm side, with energy, housing, and services contributing to the upside. That combination of sticky core inflation and still‑solid consumer spending keeps the “higher-for-longer” policy discussion very much alive. For markets, it means that rate‑cut hopes have to be tempered by the reality that the Fed can’t declare victory on inflation just yet, especially with nominal growth holding up and labor markets only gradually cooling.

Big Tech and the AI trade lose altitude

For much of the past year, the dominant equity story has been AI — and the mega‑cap platforms, cloud providers, and chipmakers enabling it. That trade is now clearly in a reassessment phase. Even as companies like Micron (MU, $1,213.56, +15.81%) deliver strong results and upbeat guidance on memory demand and AI‑linked workloads, the market is questioning how much of that good news is already in the price. Elevated valuations, massive capital expenditure plans, and rising energy and infrastructure costs are forcing investors to take a harder look at the true return on AI investment. Indeed, today’s action fit that theme. Semiconductor names and select hardware plays were able to show relative strength, benefiting from secular demand for compute and memory. But the broader tech complex — software, internet, and consumer tech — remained under pressure. The stocks most exposed to data center build‑outs, cloud AI infrastructure, and power consumption saw continued selling as markets recalibrated just how far and fast AI‑driven earnings can grow in the near term.

Factor and sector rotation beneath the surface

Beneath the index level, Thursday’s session extended a pattern that’s been building for several days. On a factor basis, value, quality, and smaller‑cap exposures outperformed momentum and high‑beta growth. On a sector level, the laggards and leaders looked notably different from the prior AI‑driven regime. Energy and parts of technology remained under pressure, reflecting both recent volatility in crude oil prices ($71.92, -23.40% over the past month) and the market’s pivot away from the highest‑multiple growth names. By contrast, industrials, selected materials, and financials showed more resilience. Banks, in particular, benefited from the prospect that persistently higher rates could support net interest margins, even as they must balance that against credit‑cycle risk. Defensive areas — such as certain staples and health care names — also saw incremental interest from investors looking to stay invested in equities while dialing down exposure to the most crowded and volatile pockets of the market. This rotation is not yet a wholesale abandonment of growth, but it is clearly a deliberate rebalancing toward cash flow visibility, balance‑sheet strength, and valuation support.

Rates, global context, and the macro narrative

The rates backdrop added another layer of complexity. Treasury yields, which had been rising on the back of strong data and revived inflation worries, eased slightly into the close. That move suggests investors see some probability that tighter financial conditions and equity volatility — especially in the tech complex — will help cool activity and inflation over time, potentially doing some of the Fed’s job for it. Globally, easing geopolitical tensions and softer crude prices have provided a modest tailwind to risk assets outside the U.S., particularly in markets like India where benchmark indices have been pushing to fresh highs as oil retreats. At the same time, currency markets and volatility gauges were relatively calm, implying that investors view today’s PCE‑driven repricing as an adjustment within the existing regime rather than the start of something structurally new.

VP Watchlist Updates

Amwell® (NYSE: AMWL) a leading provider of a comprehensive SaaS-based software platform for technology-enabled healthcare, closed at $8.40..

Eupraxia Pharmaceuticals Inc. (EPRX, $6.41, +2.56%), a clinical-stage biotechnology company leveraging its proprietary Diffusphere™ technology designed to optimize local, controlled drug delivery for applications with significant unmet need, announced (May 5) the first Eosinophilic Esophagitis Endoscopic Reference Score (EREFS) data from its ongoing Phase 1b/2a part of the RESOLVE trial evaluating EP-104GI for the treatment of eosinophilic esophagitis (“EoE”). These data were also presented at the ongoing Digestive Disease Week (“DDW”) conference in Chicago. “The EREFS is an important, validated visual index of severity of EoE disease in the esophagus of patients. It measures edema, rings and strictures and other visible markers of disease often associated with symptoms. Today’s data demonstrated improvement in two key outcomes with EP-104GI in the treatment of EoE: first, that a full injection protocol of 20 injections resulted in more pronounced improvement than a protocol with fewer injections and less coverage area within the esophagus; second, with the higher number of injections, a consistent response in both the inflammatory and fibrotic sub scores of EREFS was observed,” said Dr. James A. Helliwell, Chief Executive Officer of Eupraxia. “This EREFS data being reported at DDW is consistent with the improvements we have seen in EoE symptoms and tissue health (EoEHSS) and suggests improvement in inflammation, fibrosis and the associated narrowing of the esophagus.”

Modular Medical, Inc. (NASDAQ: MODD, $4.12), a leader in innovative, patient-centric insulin delivery, announced (June 24) that the Pivot™ tubeless insulin patch pump is now commercially available. This marks the start of real-world patient use, and the Company’s transition to a commercial-stage medical device company. As only the second fully electronic, tubeless insulin pump available in the United States, Pivot is designed to make pump therapy simpler to learn and easier to live with. Its removable two-part design and 3 mL reservoir, intuitive interface, and flexible, wearable form factor support everyday activities, such as showering and sports, with no battery recharging required – all while maintaining clinical accuracy and connectivity. “Reaching commercial availability is a transformational milestone that marks Modular Medical’s transition from a development-stage company to a revenue-generating commercial business,” said Jeb Besser, Chief Executive Officer of Modular Medical. “As only the second fully electronic tubeless pump on the U.S. market, Pivot is positioned to serve a large, underserved ‘almost-pumper’ population. With first shipments beginning this week, we are focused on disciplined execution, as we scale adoption and seek to build long-term value for patients and shareholders.”

On (June 4) the launch of PivotPump.com, a patient-focused website designed to support individuals seeking a simpler path to insulin pump therapy. This launch follows the Company’s receipt of U.S. Food and Drug Administration (“FDA”) clearance in April 2026 for its Pivot™ insulin delivery system. The FDA clearance represents a significant milestone in Modular Medical’s strategy to expand access to insulin pump technology, particularly among individuals historically underserved by existing solutions. The Company remains on track for commercial launch in the fall of 2026. Pivot is designed for people living with diabetes who rely on daily insulin injections, as well as those who have encountered technological, usability, or cost-related barriers with traditional pump systems. The system emphasizes simplicity and ease of use for the patient and full access to clinical information for the clinician to reduce adoption friction. The PivotPump.com website provides accessible, educational content on insulin pump therapy and highlights the Company’s focus on real-world usability and supporting patients in evaluating and adopting pump-based diabetes care.

Similarweb Ltd. (NYSE: SMWB, $5.15), a leading digital data and analytics company powering critical business decisions, announced (June 15) that it has surpassed $300 million in Annual Recurring Revenue (ARR) and signed two multi-year enterprise contracts, each representing seven-figure ARR commitments. Collectively, these contracts represent approximately $47 million in Total Contract Value to be recognized over the next three years and were signed during the second quarter of 2026.

Triller Group Inc (Nasdaq: ILLR, $3.05,+296.57%), a technology and media company operating Triller App, a social media and live-streaming platform focused on music, sports, fashion and culture, together with AGBA Group, a Hong Kong-based financial-services and platform business with longstanding operations in wealth distribution, healthcare and related services across Asia, today announced that it has entered into definitive agreements to acquire a significant position providing economic exposure to SpaceX to be held as a strategic treasury asset on the Company’s balance sheet.

DPC Holdings Limited (“Doncasters” or the “Company”), a portfolio company of the private equity and credit investment affiliates of J.F. Lehman & Company, LLC (“JFLCO”), completed a successful IPO and listed on the New York Stock Exchange (NYSE) on June 25, 2026, under the ticker symbol “DPC” closed at $46.88, +42.06%. Doncasters is a leading independent manufacturer of complex, highly engineered precision cast components and nickel and cobalt-based superalloys primarily serving the aerospace and IGT end markets. Doncasters intends to use its net proceeds from this offering to, among other uses, repay outstanding indebtedness and for general corporate purposes, including funding working capital and future growth projects.

The Sources

  1. CNBC – Stock market live updates (June 24, 2026)
    https://www.cnbc.com/2026/06/24/stock-market-today-live-updates.html
  2. Nasdaq – Stock Market News for Jun 25, 2026
    https://www.nasdaq.com/articles/stock-market-news-jun-25-2026
  3. Yahoo Finance – Stock market today: Dow and S&P 500 rise, Nasdaq slips as PCE comes in hot, Big Tech falters
    https://finance.yahoo.com/markets/live/stock-market-today-dow-and-sp-500-rise-nasdaq-slips-as-pce-comes-in-hot-big-tech-falters-
  4. Yahoo Finance – Core inflation rate hit 3.4% in May, highest since October 2023, Fed’s preferred gauge shows
    https://www.cnbc.com/2026/06/25/pce-inflation-report-may-2026-.html
  5. Yahoo Finance – Nasdaq, S&P 500 fall as global chip sell-off spurs AI doubts
    https://finance.yahoo.com/economy/live/stock-market-today-nasdaq-sp-500-fall-as-global-chip-sell-off-spurs-ai-doubts-230258084.html
  6. Yahoo Finance – Big Tech is dragging the S&P 500 lower in June
    https://finance.yahoo.com/video/big-tech-is-dragging-the-sp-500-lower-in-june-193121554.html
  7. The Street – Stock Market Today (June 25, 2026): Mag7 falls after Apple…
    https://www.thestreet.com/stock-market-today/stock-market-today-dow-jones-sp-500-nasdaq-updates-june-25-2026
  8. Investopedia – Stock Market Today: Nasdaq slips as Micron earnings revive…
    https://www.investopedia.com/stock-market-today-dow-jones-s-and-p-500-06252026-12006401
  9. Trading Economics – United States Stock Market Index (US500)
    https://tradingeconomics.com/united-states/stock-market
  10. Saxo Bank – Market Quick Take – 25 June 2026
    https://www.home.saxo/en-mena/content/articles/macro/market-quick-take—25-june-2026-25062026
  11. ATFX – Daily Market Highlight (June 25, 2026)
    https://www.atfx.com/en/analysis/market-news/20260625-daily-market-highlight

June 24, 2026

June 24, 2026 – AI Hangover, Micron Espresso: Dow Rallies While the Nasdaq Reaches for Advil -( $AMWL $DIA $FOUR $MU $SMWB Rise! )

The major U.S. equity benchmarks finished mixed on Wednesday, June 24, 2026, with the Dow closing higher while the S&P 500 and Nasdaq ended modestly lower as investors weighed renewed AI-chip volatility against anticipation for Micron’s earnings and the upcoming PCE inflation print. Micron’s (MU) after‑the‑bell blowout fiscal Q3 and bullish AI‑driven outlook helped stabilize sentiment in the semiconductor complex in extended trading as it rose over 14%.

U.S. Equity Index Performance

  • Dow Jones Industrial Average: Up .35% closing at 51,848.90 on Wednesday, rebounding from Tuesday’s 0.1% decline.
  • S&P 500: Roughly flat closed .10% lower on the day at 7,358.22 after Tuesday’s 1.4% drop.
  • Nasdaq Composite: Slightly negative at the close off .43% and closing at 25,476.64 as the chip complex stayed volatile; this follows Tuesday’s 2.2% slide,

Sector Moves and Market Breadth

Tech and communication services lagged again as investors trimmed exposure to high‑beta AI and semiconductor names into a pivotal Micron earnings print. By contrast, defensive pockets and select cyclicals drew incremental flows as traders rotated toward balance sheet strength and cash‑flow visibility.

Key dynamics:

  • Semiconductors: Ongoing “AI hangover” after a multi‑month melt‑up left the group vulnerable to profit‑taking ahead of Micron’s numbers.
  • Defensives/Staples: Consumer staples and other defensives outperformed again after leading on Tuesday, highlighting a gradual de‑risking under the hood.
  • Energy: Lower crude prices now at $69.84/bbl acted as a tailwind for broader risk sentiment but pressured energy equities relative to the tape.

Breadth data show more constructive participation than Tuesday’s tech‑heavy washout, with the Dow’s advance driven by a majority of components in the green while megacap tech remained bifurcated.

Micron’s AI‑Era Earnings Send a Strong Signal

Micron Technology sat squarely at the center of today’s narrative as investors looked to its fiscal Q3 results and guidance for a real‑time read on AI infrastructure demand.

From Micron’s fiscal Q3 2026 release and subsequent coverage:

  • Revenue: Micron reported fiscal Q3 revenue of about 41.5 billion dollars, more than quadrupling from roughly 9.3 billion dollars a year earlier, as AI‑driven demand for high‑bandwidth memory and data‑center products surged..
  • Profitability: GAAP net income reached roughly 28.2 billion dollars (about 24.67 per diluted share), with non‑GAAP EPS near 25.11 as gross margins expanded sharply on higher prices and improved mix.
  • Outlook: Management guided for Q4 revenue around 50 billion dollars, far above the prior‑year period, underscoring confidence in sustained AI‑related demand.
  • Capital returns: The board declared a quarterly 0.15‑per‑share cash dividend payable July 21, 2026 to holders of record as of July 6, 2026, reinforcing Micron’s transition into a structurally more cash‑generative phase.

AI Trade: From Euphoria to Scrutiny

Tuesday’s sharp declines in the Nasdaq and semiconductor sector reflected growing unease that AI capex and earnings expectations had disconnected from near‑term fundamentals. By Wednesday, the tone shifted from outright de‑risking to more nuanced stock‑picking around balance sheets, backlog visibility, and exposure to AI data‑center build‑outs.

Macro Backdrop: All Eyes on PCE and the Fed

Wednesday’s session also served as a positioning day ahead of Thursday’s May personal consumption expenditures (PCE) price index, the Fed’s preferred inflation gauge. Futures markets advanced modestly Wednesday evening, with Dow futures up about 0.2% (roughly 120 points) and S&P 500 and Nasdaq 100 futures higher by low‑single‑digit basis points as traders calibrated soft‑landing odds.

Key macro considerations:

  • Inflation trajectory: A benign PCE print would reinforce the narrative that disinflation is back on track, giving the Fed more optionality on a 2026–2027 easing path without re‑igniting inflation fears.
  • Growth vs. policy: With the U.S. 500 benchmark up over 21% year‑on‑year despite a roughly 1.7% pullback over the last month, equity bulls are effectively betting that earnings growth can outpace any remaining drag from restrictive policy.
  • Global cross‑currents: Lower oil prices (Brent around the mid‑70s per barrel and WTI in the low‑70s earlier this week) have eased some stagflation anxiety but also signal caution on global demand..

Positioning around PCE is likely to dictate the next leg for rate‑sensitive sectors (small caps, financials, REITs) and for high‑multiple growth, including AI leaders.

Credit, Commodities, and Cross‑Asset Signals

While the equity tape remains noisy, cross‑asset signals are broadly consistent with a late‑cycle, risk‑on but more selective environment.

  • Credit: Spreads remain relatively contained, suggesting no acute stress in corporate funding markets despite recent equity volatility.
  • Commodities: Crude prices near multi‑month lows have acted as a quasi‑tax cut for consumers and input‑sensitive industries, helping support cyclicals even as energy equities lag.
  • Volatility: The VIX popped more than 12% to about 19.49 on Tuesday’s selloff, underscoring how crowded AI trades can amplify downside, but remains well below crisis levels.

Biotech, Pharma, and Rate‑Sensitive Growth

Even though Wednesday’s headlines were dominated by Micron and AI, the recent rate and inflation backdrop continues to matter for biotech and long‑duration growth.

  • Lower yields and contained inflation expectations favor development‑stage biotech and platform‑driven pharma stories that are sensitive to discount‑rate assumptions.
  • However, the market’s growing focus on realized cash flows means that later‑stage, near‑commercial names and royalty platforms may see more durable sponsorship than binary clinical‑readout stories..

VP Watchlist Updates

Amwell® (NYSE: AMWL) a leading provider of a comprehensive SaaS-based software platform for technology-enabled healthcare, closed at $8.49, +1.92%%.

Eupraxia Pharmaceuticals Inc. (EPRX, $6.25), a clinical-stage biotechnology company leveraging its proprietary Diffusphere™ technology designed to optimize local, controlled drug delivery for applications with significant unmet need, announced (May 5) the first Eosinophilic Esophagitis Endoscopic Reference Score (EREFS) data from its ongoing Phase 1b/2a part of the RESOLVE trial evaluating EP-104GI for the treatment of eosinophilic esophagitis (“EoE”). These data were also presented at the ongoing Digestive Disease Week (“DDW”) conference in Chicago. “The EREFS is an important, validated visual index of severity of EoE disease in the esophagus of patients. It measures edema, rings and strictures and other visible markers of disease often associated with symptoms. Today’s data demonstrated improvement in two key outcomes with EP-104GI in the treatment of EoE: first, that a full injection protocol of 20 injections resulted in more pronounced improvement than a protocol with fewer injections and less coverage area within the esophagus; second, with the higher number of injections, a consistent response in both the inflammatory and fibrotic sub scores of EREFS was observed,” said Dr. James A. Helliwell, Chief Executive Officer of Eupraxia. “This EREFS data being reported at DDW is consistent with the improvements we have seen in EoE symptoms and tissue health (EoEHSS) and suggests improvement in inflammation, fibrosis and the associated narrowing of the esophagus.”

Modular Medical, Inc. (NASDAQ:MODD, $4.195), a leader in innovative, patient-centric insulin delivery, announced (June 24) that the Pivot™ tubeless insulin patch pump is now commercially available. This marks the start of real-world patient use, and the Company’s transition to a commercial-stage medical device company. As only the second fully electronic, tubeless insulin pump available in the United States, Pivot is designed to make pump therapy simpler to learn and easier to live with. Its removable two-part design and 3 mL reservoir, intuitive interface, and flexible, wearable form factor support everyday activities, such as showering and sports, with no battery recharging required – all while maintaining clinical accuracy and connectivity. “Reaching commercial availability is a transformational milestone that marks Modular Medical’s transition from a development-stage company to a revenue-generating commercial business,” said Jeb Besser, Chief Executive Officer of Modular Medical. “As only the second fully electronic tubeless pump on the U.S. market, Pivot is positioned to serve a large, underserved ‘almost-pumper’ population. With first shipments beginning this week, we are focused on disciplined execution, as we scale adoption and seek to build long-term value for patients and shareholders.”

On (June 4) the launch of PivotPump.com, a patient-focused website designed to support individuals seeking a simpler path to insulin pump therapy. This launch follows the Company’s receipt of U.S. Food and Drug Administration (“FDA”) clearance in April 2026 for its Pivot™ insulin delivery system. The FDA clearance represents a significant milestone in Modular Medical’s strategy to expand access to insulin pump technology, particularly among individuals historically underserved by existing solutions. The Company remains on track for commercial launch in the fall of 2026. Pivot is designed for people living with diabetes who rely on daily insulin injections, as well as those who have encountered technological, usability, or cost-related barriers with traditional pump systems. The system emphasizes simplicity and ease of use for the patient and full access to clinical information for the clinician to reduce adoption friction. The PivotPump.com website provides accessible, educational content on insulin pump therapy and highlights the Company’s focus on real-world usability and supporting patients in evaluating and adopting pump-based diabetes care.

Similarweb Ltd. (NYSE: SMWB, $5.16, +3.82%), a leading digital data and analytics company powering critical business decisions, announced (June 15) that it has surpassed $300 million in Annual Recurring Revenue (ARR) and signed two multi-year enterprise contracts, each representing seven-figure ARR commitments. Collectively, these contracts represent approximately $47 million in Total Contract Value to be recognized over the next three years and were signed during the second quarter of 2026.

Loman AI, the leading Voice AI for restaurants, announced (June 3) a partnership with Shift4 (NYSE: FOUR), $44.22, +14.35%), expanding access to its voice AI platform for restaurants using the Shift4 Dine POS system. Loman is already live with hundreds of Shift4-powered restaurants, helping operators capture more revenue, streamline operations, and deliver better guest experiences.

The Sources

  1. Yahoo Finance – “Stock market today: Dow rises, S&P 500 and Nasdaq slip as AI jitters return ahead of Micron earnings”
    https://finance.yahoo.com/markets/live/stock-market-today-dow-rises-sp-500-and-nasdaq-slip-as-ai-jitters-return-ahead-of-micron-earnings-230105138.html
  2. Yahoo Finance – “Micron tops Q3 earnings estimates, offers better‑than‑expected outlook and declares dividend”
    https://finance.yahoo.com/technology/article/micron-tops-q3-earnings-estimates-offers-better-than-expected-outlook-and-declares-dividend-113000152.html
  3. CNBC – “Stock market today: live updates for Wednesday, June 24, 2026”
    https://www.cnbc.com/2026/06/24/stock-market-today-live-updates.html
  4. CNBC – “Stock market today: live updates for Tuesday, June 23, 2026”
    https://www.cnbc.com/2026/06/23/stock-market-today-live-updates.html
  5. CNBC – “Micron stock jumps 9% as soaring prices from memory crunch lead to quadrupling of revenue”
    https://www.cnbc.com/2026/06/24/micron-mu-earnings-report-q3-2026.html
  6. Micron Technology – “Micron Technology, Inc. Reports Record Results for the Third Quarter of Fiscal 2026” (official release)
    https://investors.micron.com/node/50671/pdf
  7. Nasdaq – “Stock Market News for Jun 24, 2026”
    https://www.nasdaq.com/articles/stock-market-news-jun-24-2026
  8. Trading Economics – “United States Stock Market Index – Quote – Chart”
    https://tradingeconomics.com/united-states/stock-market
  9. The Motley Fool – “Stock Market Today, June 24: Stocks Gain at Midday Ahead of Micron’s Earnings”
    https://www.fool.com/coverage/stock-market-today/2026/06/24/stock-market-today-june-24-stocks-gain-at-midday-ahead-of-micron-s-e/
  10. 24/7 Wall St – “Stock Market Live June 24, 2026: S&P 500 (SPY) Attempting to Regain Momentum”
    https://247wallst.com/investing/2026/06/24/stock-market-live-june-24-2026-sp-500-spy-attempting-to-regain-momentum/

June 23, 2026

June 23, 2026 – From AI Euphoria to AI Hangover: Chip Meltdown Sends Nasdaq Down 2% and Markets De‑Risk -( $AMWL $ATLN $QURE Rise! )

U.S. equities finished lower across the board on Tuesday, June 23, 2026, as the AI and semiconductor unwind morphed into a broad de‑risking that hit large caps, small caps, and high‑beta tech alike

Market at the close – indices and macro

U.S. stocks sold off broadly on Tuesday, June 23, 2026, as the AI and semiconductor unwind bled into the broader tape. The S&P 500 (^GSPC) fell 1.44% to close at 7,365.46, while the Dow Jones Industrial Average (^DJI) slipped 0.09% to 51,666.84, giving up early attempts to stabilize. The tech‑heavy Nasdaq Composite (^IXIC) led the decline, dropping 2.21% to 25,587.04, with growth, AI hardware, and chip names under heavy pressure. Small caps also joined the sell‑off, with the Russell 2000 (^RUT) finishing down 0.96% at 2,975.48, underscoring that today’s move was a broad de‑risking rather than a narrow mega‑cap tech story. Macro‑wise, the tape reflected less a single data shock and more a positioning reset. Investors are reassessing how much AI‑driven capex and semiconductor earnings can justify recent valuation extremes against a backdrop of higher‑for‑longer policy rates, an uneven global growth profile, and growing concerns that corporate guidance may begin to lag AI‑inflated expectations in the second half of the year.

AI and chips – from euphoria to risk‑off

The core equity story remains the cool‑off in AI and semiconductors, which has shifted from a tactical shakeout into a firmer valuation check. Chip leaders such as Nvidia (NVDA), Micron Technology (MU), Intel (INTC), and AMD (AMD), along with broader semiconductor baskets like the VanEck Semiconductor ETF (SMH) and leveraged products such as SOXL, came under heavy pressure as investors questioned how far AI‑related demand can stretch margins and multiples. This unwinding has begun to look self‑reinforcing. As crowded AI and chip trades roll over, systematic and leveraged strategies are forced to de‑risk, adding mechanical supply into already fragile order books. The narrative tug‑of‑war between “AI euphoria” and “AI phobia” is now being settled in price action: the Nasdaq’s more than 2% decline, alongside downside in the S&P 500, signals a pivot from “growth at any price” toward “show me the cash‑flows and durability.” The weakness is not confined to U.S. shores. Selling pressure in Korean, European, and other Asian chip names has broadened the move into a global AI/semiconductor reset, reinforcing that this is a cross‑border positioning event rather than a U.S.‑only correction.

Biotech focus – uniQure (QURE) taps public markets

Against this volatile macro and AI‑driven backdrop, gene therapy specialist uniQure N.V. (QURE) stepped in to raise growth capital, announcing a $150 million underwritten public offering  this week of ordinary shares and pre‑funded warrants. The deal structure includes a 30‑day underwriters’ option to purchase additional shares, which could push gross proceeds toward roughly $172.5 million if fully exercised. Management has flagged the proceeds for late‑stage development and platform investment, with a particular focus on advancing its Huntington’s disease program AMT‑130 and other severe neurological and hematologic indications. In a market that is clearly discriminating between “science projects” and credible late‑stage platforms, QURE’s ability to tap the public markets at scale is noteworthy. It underscores that, even in a more risk‑averse tape, investors are still willing to fund differentiated IP and pipelines with tangible regulatory paths and value‑creating milestones. For biotech‑oriented investors in your audience, the juxtaposition is important: while high‑beta AI hardware is getting repriced, late‑stage gene‑therapy stories like uniQure can still access capital, provided they can clearly articulate clinical and commercial visibility.

Private equity and small‑business capital – Atlantic International / Circle8

In the private‑market and small‑business ecosystem, Atlantic International Corp. (ATLN, $1.33, +202.41%) and its Circle8 Group platform continue to illustrate where capital remains patient. Atlantic’s acquisition of Circle8 earlier this year created an integrated global workforce‑solutions platform with roughly $1.2 billion in revenue, spanning staffing, technology, and services. Subsequent multi‑year contracts and minimum‑commitment deals show that structured, recurring‑revenue models are still attracting sizable institutional and corporate capital. Today, they announced that Seven Stars B.V., a company within its Circle8 Group platform, has been awarded a four-year framework agreement by the Dutch Vehicle Authority (RDW) for the provision of specialized ICT (Information and Communications Technology) professionals. Seven Stars secured the contract through a competitive procurement process involving sixteen participants. Based on the procurement documentation, the framework agreement represents a minimum contract value of approximately $52 million over its four-year term. This award follows Circle8 Group’s recently announced public sector contract award with an estimated value of approximately $380 million and further demonstrates the platform’s ability to secure large-scale assignments in highly competitive markets.

VP Watchlist Updates

Amwell® (NYSE: AMWL) a leading provider of a comprehensive SaaS-based software platform for technology-enabled healthcare, closed at $8.33, +1.34%.

Eupraxia Pharmaceuticals Inc. (EPRX, $6.39), a clinical-stage biotechnology company leveraging its proprietary Diffusphere™ technology designed to optimize local, controlled drug delivery for applications with significant unmet need, announced (May 5) the first Eosinophilic Esophagitis Endoscopic Reference Score (EREFS) data from its ongoing Phase 1b/2a part of the RESOLVE trial evaluating EP-104GI for the treatment of eosinophilic esophagitis (“EoE”). These data were also presented at the ongoing Digestive Disease Week (“DDW”) conference in Chicago. “The EREFS is an important, validated visual index of severity of EoE disease in the esophagus of patients. It measures edema, rings and strictures and other visible markers of disease often associated with symptoms. Today’s data demonstrated improvement in two key outcomes with EP-104GI in the treatment of EoE: first, that a full injection protocol of 20 injections resulted in more pronounced improvement than a protocol with fewer injections and less coverage area within the esophagus; second, with the higher number of injections, a consistent response in both the inflammatory and fibrotic sub scores of EREFS was observed,” said Dr. James A. Helliwell, Chief Executive Officer of Eupraxia. “This EREFS data being reported at DDW is consistent with the improvements we have seen in EoE symptoms and tissue health (EoEHSS) and suggests improvement in inflammation, fibrosis and the associated narrowing of the esophagus.”

Modular Medical, Inc. (NASDAQ:MODD, $4.29), a leader in innovative, patient-centric insulin delivery, announced (June 4) the launch of PivotPump.com, a patient-focused website designed to support individuals seeking a simpler path to insulin pump therapy. This launch follows the Company’s receipt of U.S. Food and Drug Administration (“FDA”) clearance in April 2026 for its Pivot™ insulin delivery system. The FDA clearance represents a significant milestone in Modular Medical’s strategy to expand access to insulin pump technology, particularly among individuals historically underserved by existing solutions. The Company remains on track for commercial launch in the fall of 2026. Pivot is designed for people living with diabetes who rely on daily insulin injections, as well as those who have encountered technological, usability, or cost-related barriers with traditional pump systems. The system emphasizes simplicity and ease of use for the patient and full access to clinical information for the clinician to reduce adoption friction. The PivotPump.com website provides accessible, educational content on insulin pump therapy and highlights the Company’s focus on real-world usability and supporting patients in evaluating and adopting pump-based diabetes care.

Similarweb Ltd. (NYSE: SMWB, $4.97), a leading digital data and analytics company powering critical business decisions, announced (June 15) that it has surpassed $300 million in Annual Recurring Revenue (ARR) and signed two multi-year enterprise contracts, each representing seven-figure ARR commitments. Collectively, these contracts represent approximately $47 million in Total Contract Value to be recognized over the next three years and were signed during the second quarter of 2026.

The Sources

  1. Stock Market News for Jun 23, 2026 – Yahoo Finance[finance.yahoo]
  2. How Major US Stock Indexes Fared Tuesday 6/23/2026 – Yahoo Finance[finance.yahoo]
  3. Nasdaq Futures Fall 2% on Tech Worries, Fed Hike Bets – Reuters via Yahoo/Investing[finance.yahoo]
  4. Markets News, June 23, 2026: Stocks Fall as Tech Sell-Off Expands to Memory, Chips – Investopedia[investopedia]
  5. Stock Market News, June 23, 2026: Nasdaq and S&P 500 End Sharply Lower – MarketWatch Live Blog[marketwatch]
  6. Stock Market Today: Tech Slide Deepens as AI Fears Get Worse – Wall Street Journal Live Coverage[wsj]
  7. US AI Stock Sell-Off Shakes Markets from Wall Street to Asia – The Guardian[theguardian]
  8. Micron Technology Shares Plunge 13% as Global Chip Selloff Deepens – Livemint[livemint]
  9. One Factor May Keep Chip Stocks on a Roller Coaster – CNBC[cnbc]
  10. uniQure Announces $150 Million Proposed Public Offering – BioSpace[biospace]
  11. uniQure Launches $150 Million Public Share Offering – StreetInsider[streetinsider]
  12. UniQure Announces Planned $150 Million Public Offering – MarketScreener[marketscreener]
  13. Atlantic International Corp. Acquires Circle8 Group – Yahoo Finance[finance.yahoo]
  14. Atlantic International Expands its $1.2 Billion Revenue Platform – Yahoo Finance[finance.yahoo]
  15. Atlantic International Corp. (ATLN) Stock Price, News, Quote & History – Yahoo Finance[finance.yahoo]

June 23, 2026

From Yellowcake to Market Cake: Energy Fuels Bakes Vertical Integration Into the Critical Materials Trade -( $UUUU )

Energy Fuels’ (UUUU) latest definitive agreement reads like a rare earths coming‑of‑age story: a mid‑cap uranium veteran quietly positioning itself as a “mine‑to‑metal” linchpin in Western supply chains while markets are just starting to notice.

The Deal: A Rare Earths Alliance With Global Ambition

Energy Fuels has entered a definitive agreement to acquire Australian Strategic Materials (ASM) in a transaction valued at roughly 299 million USD (447 million AUD), aiming to create the first fully integrated “mine‑to‑metal” rare earths producer in the Western world. The deal is scheduled to close by the end of June 2026, subject to ASM shareholder approval and Australian regulatory sign‑offs, a timeline that should align neatly with the company’s broader critical materials build‑out.

At its core, the agreement is about control of a strategic value chain rather than just adding another project to the corporate slide deck. Energy Fuels plans to blend its U.S. resource base and processing know‑how with ASM’s downstream manufacturing capabilities, effectively stitching together mining, separation, and alloy production under one corporate roof.

From Uranium Veteran To Critical Materials Conductor

Based in the U.S., Energy Fuels has long been known as a producer of uranium, rare earth elements (REEs), vanadium, and heavy mineral sands, anchored by its White Mesa Mill in Utah. Over the last several years, management has deliberately reframed the company as a “critical materials” platform, leveraging existing infrastructure to move beyond legacy nuclear fuel narratives into defense‑grade and EV‑centric supply chains.

That evolution accelerated in mid‑2026, when the company received a conditional 725 million USD, 20‑year financing commitment from the U.S. Office of Strategic Capital to expand critical minerals processing at White Mesa and build a new rare earth metals and alloy facility in the United States. In simple terms, Washington is effectively co‑signing Energy Fuels’ transformation from uranium specialist to vertically integrated critical materials supplier.

Vertical Integration: From Ore To Magnet

The acquisition of ASM is strategically designed to complement Energy Fuels’ mine and mill footprint with downstream metal and magnet production capacity. By pairing rare earth concentrates from its projects and White Mesa processing with ASM’s technology and facilities, the company aims to deliver a Western “mine‑to‑metal” solution for customers in defense, automotive, and advanced technology sectors.

This integrated model could reduce reliance on Chinese processing and manufacturing hubs, a recurring concern for policymakers and OEMs grappling with supply chain concentration risk. For investors, the appeal lies in the potential for Energy Fuels to capture margin at multiple points along the value chain—resource extraction, chemical processing, metal making, and ultimately engineered products.

Market Reaction: A Quiet Re‑Rating In Progress

Equity markets have started to respond to the company’s strategic shift and financing momentum, with Energy Fuels shares recently moving higher following confirmation of the U.S. government’s conditional loan commitment. The 20‑year structure of the proposed financing not only stabilizes capital planning but also signals public‑sector confidence in the long‑term necessity of domestic rare earths infrastructure

Short‑term, earnings estimate revisions are still catching up to the new narrative, and analysts remain cautious about execution risk in building out a complex, multi‑stage supply chain. However, the combination of a definitive ASM deal, government‑backed financing, and a strategic pivot toward critical materials is steadily nudging the stock from “uranium cyclical” bucket toward “platform asset” status in many portfolio frameworks.

Why This Story Is Investor‑Magnetic

For investors, Energy Fuels now sits at the crossroads of several durable themes: national security, energy transition, electrification, and supply chain diversification. The planned acquisition of ASM and the conditional 725 million USD commitment form a coherent blueprint—control the ore, control the chemistry, and increasingly, control the metal and magnet output.

The next chapter will hinge on execution: permitting, construction, cost discipline, and customer contracts that translate narrative into cash flow. Yet in a market where investors often chase “picks and shovels” behind megatrends, Energy Fuels is quietly assembling something more ambitious—a spine for Western rare earths that could turn today’s definitive agreement into tomorrow’s defining rerating.

The Sources


[1] Why Energy Fuels (TSX:EFR) Is Up 11.3% After Securing a US$725 Million Government Loan Commitment https://finance.yahoo.com/energy/articles/why-energy-fuels-tsx-efr-020715308.html
[2] Energy Fuels Forges Major Rare Earths Alliance with … https://www.ad-hoc-news.de/boerse/news/ueberblick/energy-fuels-forges-major-rare-earths-alliance-with-australian-strategic/68519899
[3] Energy Fuels Receives Conditional U.S. Government … https://www.prnewswire.com/news-releases/energy-fuels-receives-conditional-us-government-support-to-accelerate-growth-in-rare-earths-and-critical-materials-302803949.html
[4] Energy Fuels Announces Q1-2026 Results https://www.prnewswire.com/news-releases/energy-fuels-announces-q1-2026-results-302764727.html
[5] Oil & Gas https://energynews.oedigital.com
[6] Energy Fuels (UUUU) Stock Jumps 8.2%: Will It Continue to Soar? https://finance.yahoo.com/markets/stocks/articles/energy-fuels-uuuu-stock-jumps-094500228.html
[7] Energy Fuels Inc. and Denison Mines Corp. Announce … https://denisonmines.com/news/energy-fuels-inc-and-denison-mines-corp-announce-1576595/
[8] Optimizing content for Perplexity and Claude – GPT SEO Pro https://gptseopro.com/blog/optimizing-content-for-perplexity-and-claude
[9] Energy Fuels and Astron Corporation Limited Execute Definitive … https://www.barchart.com/story/news/26600650/energy-fuels-and-astron-corporation-limited-execute-definitive-agreements-to-jointly-develop-the-donald-rare-earth-and-mineral-sands-project-in-australia-uranium-production-from-the-companys-us-mines-and-alternate-feed-materials-continues-to-ramp-up
[10] Best Practices https://docs.perplexity.ai/docs/agent-api/prompt-guide
[11] Energy Fuels (UUUU) Stock News & Updates | StockTitan https://www.stocktitan.net/news/UUUU/
[12] 15 Perplexity AI SEO Prompts for Humanize Text https://www.airops.com/prompts/humanize-text-perplexity-ai-seo-prompts
[13] IsoEnergy Limited. | News & Media https://www.isoenergy.ca/news-media/international-consolidated-uranium-enters-the-us-uranium-sector-with-transformational-acquisition-and-strategic-alliance-with-energy-fuels
[14] Press & New Releases https://investors.energyfuels.com/news-releases
[15] UUUU Stock Quote Price and Forecast https://www.cnn.com/markets/stocks/UUUU

Your Guide To Staying Informed In The Markets

Subscribe For Free Email Updates Access To Exclusive Research

Vista Partners — © 2026 — Vista Partners LLC (“Vista”) is a Registered Investment Advisor in the State of California. Vista is not licensed as a broker, broker-dealer, market maker, investment banker, or underwriter in any jurisdiction. By viewing this website and all of its pages, you agree to our terms. Read the full disclaimer here

Copyright © 2026 Vista Partners, LLC. All rights reserved